Mangafodipir treatment for oxaliplatin-associated neuropathy

An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Related Links:

In this study, we compared perioperative and oncologic outcomes of patients treated with either open or robot-assisted radical cystectomy and intracorporeal neobladder at a tertiary care center.MethodsThe institutional prospective bladder cancer database was queried for “cystectomy with curative intent” and “neobladder”. All patients underwent robot-assisted radical cystectomy and intracorporeal neobladder or open radical cystectomy and orthotopic neobladder for high-grade non-muscle invasive bladder cancer or muscle invasive bladder cancer with a follow-up length ≥2 years were included. A 1:1 pr...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: September 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 9Author(s): A.J. Breugom, E. Bastiaannet, P.G. Boelens, E. Van Eycken, L.H. Iversen, A. Martling, R. Johansson, T. Evans, S. Lawton, K.M. O'Brien, H. Ortiz, R. Janciauskiene, O.M. Dekkers, H.J.T. Rutten, G.J. Liefers, V.E.P.P. Lemmens, C.J.H. van de VeldeAbstractIntroductionThe aim of this EURECCA international comparison is to compare oncologic treatment strategies and relative survival of patients with stage I–III rectal cancer between European countries.Material and methodsPopulation-based national cohort data from the ...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
This study identified chemotherapeutic agents that up-regulate programmed cell death ligand-1 (PD-L1) and galectin-9 (Gal-9) in breast cancer cells. Immunohistochemical (IHC) staining was used to evaluate changes in PD-L1 and Gal-9 expression in the tumor tissue of triple-negative breast cancer (TNBC) patients who received anthracycline- and taxane-based neoadjuvant chemotherapy. To determine whether PD-L1 and Gal-9 expression changes were attributable directly to chemotherapeutics, MDA-MB-231 cells and HS578 T cells were treated with different concentrations of anthracycline and taxane. Expression levels of PD-L1 a...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Conclusion: We propose a simple gene expression signature of only three RNA species could be employed clinically to predict pCR in TNBC patients receiving NAC.Cell Physiol Biochem 2018;48:2539 –2548
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
CONCLUSION: This approach merging qualitative and quantitative data suggests that mMCC patients report a better experience with avelumab than with chemotherapy. PMID: 30107762 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
Abstract Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in the treatment of advanced non-small-cell lung cancer (NSCLC) with leptomeningeal metastases (LM); however, a proportion of the patients with resistant tumors do not benefit from EGFR-TKI treatment. In the present study the case of a female patient with advanced lung adenocarcinoma harboring the EGFR L858R mutation (encoded in exon 21) who developed intracranial metastases following treatment with erlotinib after gefitinib failure is reported. The patient achieved a partial response (PR) after four cycles of chemothera...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
Conditions:   Gastric Cancer;   Chemotherapy Effect Intervention:   Drug: Chemotherapy Sponsor:   LI CHEN Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cervical Cancer Interventions:   Biological: Pembrolizumab;   Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Placebo to pembrolizumab Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Bristol-Myers Squibb Co said on Friday the U.S. Food and Drug Administration approved its treatment, Opdivo, for patients whose lung cancer had progressed even after undergoing chemotherapy and at least one other therapy.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The objective of this study was evaluation of the bioactivity of a supplement consisting of capsules with a blend of 9 probiotic organisms of the genera Lactobacillus and Bifidobacterium plus 10 digestive enzymes, in protecting the human gastrointestinal tract from chemotherapy and an antibiotic. We used the Simulator of Human Intestinal Microbial Ecosystem (SHIME) model, an in vitro model of a stable colon microbiota, and introduced 5-fluorouracil (5-FU) and vancomycin as microbiome-disrupting drugs. The probiotic with digestive enzymes supplement, added in capsules at in vivo doses, improved fermentation activity in the ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Health | Neurology